Immuron Limited (IMRN) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Jun 30 2025 to Jun 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Immuron Limited  (NASDAQ: IMRN)


Immuron Limited's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Immuron Limited's ROI in the fourth quarter of 2025?
Immuron Limited recorded a cumulative net loss of $-5 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on investment (ROI) of -65.53%.

Within the Healthcare sector 587 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from 0 to 4094.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Jun 30 2024)
IV. Quarter
Y / Y Investment Change TTM -37.14 % -35.31 % -35.49 % -16.79 % -18.51 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 5 5 13 8 9
Return On Investment (TTM) -65.53 % -79.06 % -72.35 % -60.36 % -54.78 %
IMRN's Overall Ranking # 4094 # 0 # # #
Seq. Investment Change TTM -9.28 % -8.49 % -16.57 % -9.25 % -6.63 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -5 -7 -7 -7 -7

IMRN Company Profile >> Back to IMRN Roi Comparisons >> See Annual IMRN Return On Investment



Return On Investment IMRN's Ranking
Within: No.
Industry # 255
Sector # 588
Overall # 4094

Return On Investment Statistics
High Average Low
-18.5 %
-57.28 %
-89.73 %
(Jun 30 2023)   (Jun 30 2019)



  News about Immuron Limited Return on Investment ROI

Immurons Travelan Sales Surge Amidst Financial Hurdles,

October 15, 2024

Immuron Limited Reports Sustained Sales Momentum for Travelan amidst Financial Challenges MELBOURNE, Australia, Oct. 15, 2024 Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian-based and globally integrated biopharmaceutical company, proudly announced the continued strong sales growth of its over-the-counter immune supplement, Travelan. Designed to combat pathogenic bacteria and neutralize toxins in the gastrointestinal tract, Travelan has experienced a notable increase in unaudited sales, reinforcing its position in the market as an effective remedy for travelers seeking immune support.Despite Travelan s impressive sales trajectory, Immuron Limited reported a cumulative net loss of $4 million for the fiscal year ending in the fourth quarter of 2023. This financial outcome equates to a negative return on investment (ROI) of -19.15%, a figure that underscores the company s ongoing financial challenges within the competitive healthcare sector. While Travelan continues to thrive, Immuron Limited faced a relatively lower ROI ranking, with 347 other companies in the sector outperforming in terms of investment returns.

Immuron Files Pre-IND Application with FDA for IMM-529, Stocks Surge 17.82% in Five Trading Days.

July 2, 2024

Immuron Requests Pre-IND Meeting with FDA for IMM-529 and Shares Soar 17.82% in Five Trading Days
Melbourne, Australia - Immuron Limited (ASX: IMC; NASDAQ: IMRN), a leading global biopharmaceutical company based in Australia, is excited to announce the submission of a pre-IND (investigational new drug) application to the United States Food and Drug Administration (FDA) for IMM-529, a groundbreaking therapeutic candidate. This remarkable achievement marks a significant milestone in Immuron s mission to develop innovative solutions for improving human health and solidifies its position as a frontrunner in the biopharmaceutical industry.
The pre-IND application showcases Immuron s commitment to advancing the development of IMM-529, which has shown great promise in preclinical studies. Designed to address a critical unmet medical need, IMM-529 has the potential to revolutionize the treatment landscape for a range of diseases. By seeking the FDA s approval through the pre-IND process, Immuron aims to accelerate the clinical development of IMM-529, thus bringing this potentially life-changing therapeutic option to patients in need at an expedited pace.





Financial Statements
Immuron Limited's IV. Quarter Investments $ 5 Millions IMRN's Balance sheet
Immuron Limited's IV. Quarter Income $ -5 Millions Quarterly IMRN's Income Statement
IMRN's Income by Division See IMRN's Income by Division


IMRN Annual Return On Investment (Jun 30 2025)
2025		 (Jun 30 2024)
2024		 (Jun 30 2023)
2023		 (Jun 30 2022)
2022		 (Jun 30 2021)
2021
Total Investments in Millions 8 13 20 16 19
Y / Y Investment Growth -36.47 % -37.21 % 25.87 % -16.34 % 394.33 %
Net Income in Millions -5 -7 -4 0 -8
Y / Y Net Income Growth - - - - -
Annual Return On Investment -63.89 % -53.98 % -18.5 % 0 % -43.13 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
IMRN's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for IMRN's Competitors
Subscribers only: Roi for Immuron Limited's Suppliers
Subscribers only: Return On Investment for IMRN's Customers

Other Ratios
IMRN's Roa IMRN's Inventory Turnover Ratio IMRN's Growth Rates IMRN's Dividend Statistics
IMRN's Profitability Ratios IMRN's Asset Turnover Ratio IMRN's Dividend Growth
IMRN's Roe IMRN's Valuation Ratios IMRN's Financial Strength Ratios IMRN's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2025, within Healthcare Sector ROI

Date modified: 2026-07-07T11:25:07+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.